The current stock price of SIBN is 16.58 USD. In the past month the price decreased by -15.92%. In the past year, price decreased by -1.07%.
ChartMill assigns a technical rating of 1 / 10 to SIBN. When comparing the yearly performance of all stocks, SIBN turns out to be only a medium performer in the overall market: it outperformed 56.23% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to SIBN. The financial health of SIBN is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months SIBN reported a non-GAAP Earnings per Share(EPS) of -0.51. The EPS increased by 44.57% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -9.29% | ||
| ROE | -12.64% | ||
| Debt/Equity | 0.21 |
15 analysts have analysed SIBN and the average price target is 26.41 USD. This implies a price increase of 59.27% is expected in the next year compared to the current price of 16.58.
For the next year, analysts expect an EPS growth of 28.75% and a revenue growth 19.98% for SIBN
SI-BONE, Inc. is a medical device company, which engages in the provision of a proprietary minimally invasive surgical implant system to fuse the sacroiliac joint for treatment of musculoskeletal disorders of the sacropelvic anatomy. The company is headquartered in Santa Clara, California and currently employs 349 full-time employees. The company went IPO on 2018-10-17. The firm specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The firm's products include a series of patented titanium implants, and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The firm's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant.
SI-BONE INC
471 El Camino Real, Suite 101
Santa Clara CALIFORNIA 95050 US
CEO: Jeffrey W. Dunn
Employees: 349
Phone: 14082070700
SI-BONE, Inc. is a medical device company, which engages in the provision of a proprietary minimally invasive surgical implant system to fuse the sacroiliac joint for treatment of musculoskeletal disorders of the sacropelvic anatomy. The company is headquartered in Santa Clara, California and currently employs 349 full-time employees. The company went IPO on 2018-10-17. The firm specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The firm's products include a series of patented titanium implants, and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The firm's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant.
The current stock price of SIBN is 16.58 USD. The price increased by 0.18% in the last trading session.
SIBN does not pay a dividend.
SIBN has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
SI-BONE INC (SIBN) has a market capitalization of 719.41M USD. This makes SIBN a Small Cap stock.
SI-BONE INC (SIBN) will report earnings on 2026-02-23, after the market close.